Credit Suisse Ag Viking Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 89,793 shares of VKTX stock, worth $5.68 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

89,793

Previous 88,288 1.7%

Holding current value

$5.68 Million

Previous $1.64 Million 348.14%

% of portfolio

0.01%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$17.4 - $94.5 $26,186 - $142,222	1,505 Added 1.7%	89,793 $7.36 Million
Q4 2023 Feb 08, 2024	SELL	$9.24 - $19.64 $69,540 - $147,810	-7,526 Reduced 7.85%	88,288 $1.64 Million
Q3 2023 Nov 13, 2023	SELL	$10.92 - $16.0 $192,301 - $281,760	-17,610 Reduced 15.53%	95,814 $1.06 Million
Q2 2023 Aug 11, 2023	BUY	$14.84 - $24.79 $888,129 - $1.48 Million	59,847 Added 111.7%	113,424 $1.84 Million
Q1 2023 May 10, 2023	BUY	$8.08 - $17.33 $432,902 - $928,489	53,577 New	53,577 $892,000
Q2 2022 Aug 12, 2022	SELL	$2.11 - $3.15 $103,596 - $154,658	-49,098 Reduced 99.93%	36 $0
Q1 2022 May 16, 2022	SELL	$3.0 - $4.88 $3,684 - $5,992	-1,228 Reduced 2.44%	49,134 $148,000
Q4 2021 Feb 14, 2022	BUY	$4.6 - $6.72 $27,563 - $40,266	5,992 Added 13.5%	50,362 $231,000
Q3 2021 Nov 12, 2021	BUY	$5.58 - $7.04 $26,689 - $33,672	4,783 Added 12.08%	44,370 $279,000
Q2 2021 Aug 16, 2021	SELL	$5.19 - $6.73 $132,687 - $172,059	-25,566 Reduced 39.24%	39,587 $237,000
Q1 2021 May 14, 2021	SELL	$5.74 - $9.67 $492,319 - $829,395	-85,770 Reduced 56.83%	65,153 $413,000
Q4 2020 Feb 12, 2021	SELL	$5.3 - $6.71 $350,377 - $443,591	-66,109 Reduced 30.46%	150,923 $849,000
Q3 2020 Nov 13, 2020	BUY	$5.73 - $8.11 $166,874 - $236,187	29,123 Added 15.5%	217,032 $1.26 Million
Q2 2020 Aug 12, 2020	BUY	$4.35 - $8.08 $272,701 - $506,535	62,690 Added 50.06%	187,909 $1.35 Million
Q1 2020 May 13, 2020	SELL	$3.45 - $7.95 $49,945 - $115,092	-14,477 Reduced 10.36%	125,219 $585,000
Q4 2019 Feb 12, 2020	BUY	$6.38 - $8.73 $640,271 - $876,107	100,356 Added 255.1%	139,696 $1.12 Million
Q3 2019 Nov 12, 2019	BUY	$6.55 - $8.6 $31,891 - $41,873	4,869 Added 14.12%	39,340 $270,000
Q2 2019 Aug 14, 2019	SELL	$7.67 - $10.63 $27,259 - $37,779	-3,554 Reduced 9.35%	34,471 $286,000
Q1 2019 May 14, 2019	BUY	$7.58 - $9.94 $58,062 - $76,140	7,660 Added 25.23%	38,025 $378,000
Q4 2018 Feb 13, 2019	BUY	$7.16 - $16.21 $217,413 - $492,216	30,365 New	30,365 $233,000
Q3 2018 Nov 13, 2018	SELL	$9.7 - $19.65 $838,933 - $1.7 Million	-86,488 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $335,573 - $1.1 Million	86,488 New	86,488 $821,000

Others Institutions Holding VKTX

# of Institutions

442

Shares Held

63.3M

Call Options Held

6.23M

Put Options Held

2.97M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.86B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account